NeuroPace Reports Strong Q1 Results, Raises Full-Year Revenue Guidance, Progresses FDA Approval
Summary
NeuroPace announced strong first-quarter financial results, beating revenue expectations and raising its full-year guidance, while also making progress on a key FDA approval for market expansion.
Key Events
-
Exceeded Q1 Revenue Guidance
Reported total revenue of $22.1 million for Q1 2026, surpassing the high end of its previous guidance range of $21 million to $22 million.
-
Raised Full-Year Revenue Guidance
Increased full-year 2026 revenue guidance to $99 million-$101 million, up from the prior range of $98 million-$100 million, reflecting underlying RNS growth of 21% to 23%.
-
Improved Adjusted EBITDA Outlook
Adjusted EBITDA guidance for full-year 2026 was improved to a loss between ($8.5) million and ($9.5) million, compared to previous guidance of ($9.0) million to ($10.0) million.
-
Progress on FDA Indication Expansion
Completed the FDA mid-cycle review meeting for the NAUTILUS PMA supplement, consistent with the expected regulatory timeline for potential approval in mid-2026 for idiopathic generalized epilepsy (IGE).
Analysis
NeuroPace reported first-quarter revenue of $22.1 million, exceeding the high end of its previously issued guidance. The company also raised its full-year 2026 revenue guidance to $99 million-$101 million and improved its Adjusted EBITDA outlook. This positive financial performance is coupled with significant progress on the NAUTILUS PMA supplement for idiopathic generalized epilepsy (IGE) indication expansion, with a mid-cycle FDA review completed, indicating potential market expansion in mid-2026.
At the time of this filing, NPCE was trading at $15.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $536.4M. The 52-week trading range was $7.56 to $19.60. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.